Navigating Tariffs, Litigation, and Settlements: The Multifaceted Challenge for Bayer

Bayer's US leadership reaffirms its 2026 financial guidance, citing existing trade provisions. The firm faces new tariffs, legal challenges, and leadership changes.

Bayer’s leadership in the United States has affirmed its full-year financial outlook remains unchanged, despite the imposition of new U.S. import tariffs on pharmaceutical products. In a statement to Reuters on Tuesday, Sebastian Guth, President of Bayer U.S., clarified that the company’s existing guidance had already accounted for such potential trade developments.

This confidence stems from a trade agreement between the United States and the European Union that caps duties on medicines imported from the EU at 15 percent. In March, the German life sciences group projected an adjusted EBITDA of between €9.6 billion and €10.1 billion for 2026, a figure marginally above the €9.669 billion reported for the previous year.

A Notable Absence from Tariff Exemptions

A separate trade dynamic is unfolding in Washington. Sixteen of the world’s largest pharmaceutical firms have already inked agreements with the Trump administration to exempt specific drug shipments from the new tariffs. Bayer is not among them. Guth declined to comment on whether the company is engaged in parallel negotiations to secure a similar deal.

Meanwhile, Bayer is pursuing price increases for new pharmaceuticals in Europe, Japan, and other key markets. This strategy exists in direct tension with simultaneous cost-containment pressures from U.S. policymakers—a structural conflict unlikely to see a swift resolution. A leadership change is also on the horizon for the company’s U.S. operations, with Nelson Ambrogio set to take the helm of Bayer U.S. Pharmaceuticals starting May 1.

Legal Milestones and Financial Resolutions Loom

A potentially more consequential date for the company is April 27. On that day, the U.S. Supreme Court will hear Bayer’s argument that the federal FIFRA law preempts state-level lawsuits concerning the absence of cancer warnings on glyphosate-based products. The legal position is now supported by the Trump administration, marking a shift from the stance taken during the Biden era. Furthermore, three U.S. states, most recently Kentucky, have passed legislation designed to shield Bayer from such litigation at the state level.

The glyphosate litigation, inherited through the 2018 acquisition of Monsanto, has resulted in settlement and judgment payments exceeding $11 billion to date. Progress is being made on a major settlement front: a Missouri judge has granted preliminary approval to a proposed $7.25 billion Roundup settlement. Claimants retain the right to opt out of this agreement until June 4.

Looking ahead, Bayer’s management anticipates a negative free cash flow of approximately €5 billion for 2026. The company’s share price currently trades roughly 20 percent below its February peak for the year. Investors will be watching closely for updates at the Annual Stockholders’ Meeting on April 24, followed by the release of first-quarter results on May 12. These events will test the resilience of the confident guidance recently reaffirmed by management.